ResMed (RMD) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $252.86 -0.08%
Revenue Growth %: +6.9%
Financial Fact:
Research and development: 34.45M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +6.9%
Financial Fact:
Research and development: 34.45M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q3 EPS of $2.37, $0.02 worse than the analyst estimate of $2.39. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.29 billion.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Caldwell sells IQTalent subsidiary to WinMil for C$4.7M
- Northrop Grumman wins $43.8M Navy contract for Trident II facility
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
